NCT07365319Phase 2, phase 3Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Study sponsor: Eikon Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2035-12-31Estimated
Enrollment · participants750Estimated
Source updated2026-11-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source